Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
120 participants
INTERVENTIONAL
2011-04-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. can this zinc administration cause molecular-level changes in the Barrett's tissue?
2. are the changes measured indicative of chemopreventive action by zinc regarding cancer progression?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
NCT01373125
Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor
NCT00161200
Impact of RFA on Esophageal Distensibility and Mucosal Impedance
NCT07126535
Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus
NCT02688114
Confocal Laser Endomicroscopy vs Conventional Histology for the Identification of Intestinal Metaplasia
NCT02632682
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zinc
zinc gluconate
26.6 mg zinc BID (as zinc gluconate)
sodium
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zinc gluconate
26.6 mg zinc BID (as zinc gluconate)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sharpe-Strumia Research Foundation
OTHER
Main Line Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James M. Mullin, Ph.D.
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lankenau Institute for Medical Research
Wynnewood, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F/N-R-11-3038L
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.